BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 4, 2026
Home » Authors » Lynn Yoffee

Lynn Yoffee

lynn.yoffee@clarivate.com
Articles

ARTICLES

Stents for PAD with a new twist: vascular magnetic intervention

April 20, 2010
By Lynn Yoffee

FDA clears Cambridge Heart's test for sudden cardiac arrest

April 19, 2010
By Lynn Yoffee

Panasonic to sell hearing aids to U.S. golden boomer market

April 16, 2010
By Lynn Yoffee
Jan. 1, 2011 will mark the era of the golden boomers, when they officially start to retire. This massive generation is getting older and along with that comes the decline of health, which presents opportunities for many companies to target with new product offerings. Consumer electronics giant Panasonic (Osaka, Japan) sees just such an opportunity to be part of that golden age and has decided to enter the hearing care business in the U.S. market. (Medical Device Daily)
Read More

Headset allows anesthesiologists to stay focused on the patients

April 15, 2010
By Lynn Yoffee

Supramap to aid in war against stealthy, evolving pathogens

April 14, 2010
By Lynn Yoffee

Sanuwave's dermaPACE in pivotal trial for foot ulcers

April 9, 2010
By Lynn Yoffee
Rather than treating a wound, Sanuwave Health's (Alpharetta, Georgia) dermaPACE technology harnesses the power of regenerative medicine to stimulate the body's own biological healing mechanism. With enrollment just completed in a pivotal phase III trial of dermaPACE to treat diabetic foot ulcers, the company is closer to launching a product that could address a $2 billion market in the U.S. and an estimated $10 billion advanced wound care market globally. (Medical Device Daily)
Read More

Improved device permits rapid review of circulating tumor cells

April 7, 2010
By Lynn Yoffee

Deals roundup: CareFusion buys Medegen for $225 million in cash

April 6, 2010
By Lynn Yoffee

Urovalve's Surinate bladder device aims to improve quality of life

April 5, 2010
By Lynn Yoffee

Product Briefs: DentalVibe brings good vibes to painful dental injections

April 1, 2010
By Lynn Yoffee
View All Articles by Lynn Yoffee

Popular Stories

  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • Nerves within a melanoma tumor

    Innervation can slow, as well as speed, tumor growth, study finds

    BioWorld
    Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
  • Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

    BioWorld Science
    Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing